New Biopsy Technology Analyzes Multiple Tumor Tissue Biomarkers Simultaneously

By HospiMedica International staff writers
Posted on 12 Jan 2022

Illustration

A next-generation biopsy tool will enable scientists and clinicians to simultaneously profile many biomarkers in cells and tissues.

Researchers at the University of California, Irvine (Irvine, CA, USA) have developed a new biopsy technology that can profile multiple tumor microenvironment biomarkers simultaneously, revealing cellular spatial organization and interactions that will help advance personalized disease diagnosis and treatment. Current single-biomarker biopsies lack the ability to analyze many different markers and often fail to predict patient outcomes.

Called the Multi Omic Single-scan Assay with Integrated Combinatorial Analysis, the fluorescence imaging-based technology can spatially profile a large number of mRNA and protein markers in cells and tissues, including clinical tumor tissues. Their study showed that MOSAICA enables direct, highly multiplexed biomarker profiling in a 3D spatial context using a single round of staining and imaging instead of the repeated processing steps typically needed in conventional methods. Clinicians and scientists will now have a holistic view of the different immune and cancer cell types in tumor tissues, providing greater insight for determining patient prognosis and treatment.

“Spatial biology is a new science frontier and mapping out each cell and its function in the body at both the molecular and tissue level is fundamental to understanding disease and developing precision diagnostics and therapeutics,” said Weian Zhao, Ph.D., UCI professor of pharmaceutical sciences and study co-corresponding author. “Many cancer immunotherapeutics, including immune checkpoint inhibitors, don’t work and scientists realized that was because of the spatial organization of all the tumor tissue cell types, which dictates drug efficacy. The MOSAICA can characterize the spatial cellular compositions and interactions in the tumor immune microenvironment in biopsies to inform personalized diagnosis and treatment.”

Related Links:
University of California, Irvine